CN113854574B - 一种新型复方骨肽及其应用 - Google Patents
一种新型复方骨肽及其应用 Download PDFInfo
- Publication number
- CN113854574B CN113854574B CN202111182578.XA CN202111182578A CN113854574B CN 113854574 B CN113854574 B CN 113854574B CN 202111182578 A CN202111182578 A CN 202111182578A CN 113854574 B CN113854574 B CN 113854574B
- Authority
- CN
- China
- Prior art keywords
- bone
- peptide
- bone peptide
- hours
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 123
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 106
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 241000283690 Bos taurus Species 0.000 claims abstract description 23
- 238000010521 absorption reaction Methods 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 230000008468 bone growth Effects 0.000 claims abstract description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000037182 bone density Effects 0.000 claims abstract description 7
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 7
- 239000011575 calcium Substances 0.000 claims abstract description 7
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 102000000503 Collagen Type II Human genes 0.000 claims abstract description 5
- 108010041390 Collagen Type II Proteins 0.000 claims abstract description 5
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 5
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 5
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 5
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 5
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 5
- 235000018735 Sambucus canadensis Nutrition 0.000 claims abstract description 5
- 239000004376 Sucralose Substances 0.000 claims abstract description 5
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 5
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 5
- 235000007123 blue elder Nutrition 0.000 claims abstract description 5
- 229940036811 bone meal Drugs 0.000 claims abstract description 5
- 239000002374 bone meal Substances 0.000 claims abstract description 5
- 239000005018 casein Substances 0.000 claims abstract description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000021240 caseins Nutrition 0.000 claims abstract description 5
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 5
- 235000007124 elderberry Nutrition 0.000 claims abstract description 5
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 5
- 235000008995 european elder Nutrition 0.000 claims abstract description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 5
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 5
- 235000020744 piper nigrum extract Nutrition 0.000 claims abstract description 5
- 235000019408 sucralose Nutrition 0.000 claims abstract description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 5
- 235000013976 turmeric Nutrition 0.000 claims abstract description 5
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 5
- 239000011719 vitamin A Substances 0.000 claims abstract description 5
- 235000021119 whey protein Nutrition 0.000 claims abstract description 5
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 5
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 5
- 239000000230 xanthan gum Substances 0.000 claims abstract description 5
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 23
- 235000015278 beef Nutrition 0.000 claims description 20
- 238000005238 degreasing Methods 0.000 claims description 20
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 18
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- 238000010411 cooking Methods 0.000 claims description 5
- 108090000145 Bacillolysin Proteins 0.000 claims description 4
- 102000035092 Neutral proteases Human genes 0.000 claims description 4
- 108091005507 Neutral proteases Proteins 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 229940001941 soy protein Drugs 0.000 claims description 4
- 238000005728 strengthening Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 241000208829 Sambucus Species 0.000 claims 2
- 244000151637 Sambucus canadensis Species 0.000 abstract description 3
- 229930003316 Vitamin D Natural products 0.000 abstract description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 235000019166 vitamin D Nutrition 0.000 abstract description 2
- 239000011710 vitamin D Substances 0.000 abstract description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract description 2
- 229940046008 vitamin d Drugs 0.000 abstract description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 1
- 229940071440 soy protein isolate Drugs 0.000 abstract 1
- 229940045997 vitamin a Drugs 0.000 abstract 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 20
- 229960002591 hydroxyproline Drugs 0.000 description 20
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 20
- HVIBGVJOBJJPFB-OFQRNFBNSA-N Gly-Pro-Hyp Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)C(O)CC1 HVIBGVJOBJJPFB-OFQRNFBNSA-N 0.000 description 16
- 108010017349 glycyl-prolyl-hydroxyproline Proteins 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- -1 Anti-cancer Substances 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 240000003394 Malpighia glabra Species 0.000 description 1
- 235000014837 Malpighia glabra Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 244000134540 Polymnia sonchifolia Species 0.000 description 1
- 235000003406 Polymnia sonchifolia Nutrition 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/342—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of collagen; of gelatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/20—Meat products; Meat meal; Preparation or treatment thereof from offal, e.g. rinds, skins, marrow, tripes, feet, ears or snouts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
本发明提供一种新型复方骨肽，原料中包括：牛骨多肽、Ⅱ型胶原蛋白肽、酪蛋白磷酸肽、乳清蛋白、大豆分离蛋白、酶解骨粉、麦芽糊精、维生素A、维生素D、维生素C、低聚果糖、接骨木莓果汁粉、姜黄、黑胡椒提取物、香精、黄原胶、三氯蔗糖。本发明的新型复方骨肽可应用于促进骨骼生长、促进钙质吸收、增强骨密度、改善骨质疏松。该复方骨肽吸收速率和吸收率均属于高水平，且临床施用量少，有广泛的应用前景。
Description
技术领域
本发明属于生物医药领域，具体涉及一种新型复方骨肽及其应用。
背景技术
胶原蛋白是构成细胞外基质的主要大分子之一，牛骨肽是牛骨胶原蛋白的酶解法获得的活性肽，是将牛骨胶原蛋白的三螺旋结构彻底打开，肽链被降解成为短的肽链，得到分子质量在几千道尔顿之间的多肽混合物，这些小分子肽与生物体相容性好，具有优于蛋白质和氨基酸的营养功能。同时，其具有良好的溶解性，物理性质稳定，不同来源和不同酶解工艺得到的小分子肽具有不同的生物活性，如免疫调节、降血压、降血糖、降血脂、抗衰老、抗氧化、抗癌、抗微生物、抗毒素、增加骨密度、改善骨骼韧性等。
牛骨肽富含多种非必需氨基酸，如甘氨酸(Gly)、脯氨酸(Pro)和羟脯氨酸(Hyp)，羟脯氨酸(hydroxyproline，HYP)是胶原组织主要成分之一，且为胶原中特有的氨基酸，约占胶原氨基酸总量的13％。利用血液中的羟脯氨酸为多种胶原肽的降解产物，其作为骨吸收标志物这一特点，通过对血清中羟脯氨酸的含量进行测定，可以衡量样品给药后小鼠对骨肽的吸收和生物利用度情况。此外，文献研究表明小鼠可直接吸收骨肽样品多肽混合物中的胶原三肽Gly-Pro-Hyp，因此对小鼠体内的此三肽的测量也是评价骨肽吸收和生物利用情况的另一关键指标。
牛骨肽自身的功效在与其他成分复配后可能起到更好的作用。
中国专利201710938888.7中公开的一种牛骨肽固体饮料，包含：牛骨肽、玛卡粉、蛹虫草粉剂、维生素B、维生素C、酸枣粉、金银花粉、茯苓粉、党参粉、雪莲果粉、食用香精。该发明可以替代传统的煲牛骨汤的工艺，直接加温水就可以饮用，并且喝完这种牛骨肽固体饮料要比传统要比传统牛骨汤容易吸收和消化，而且具有抗疲劳、增强精力、平衡荷尔蒙、增强免疫、抗疲劳、抗贫血、安神、健脾胃、补气兼能养血、促进消化和调理胃肠道的功效，适合不同年龄段的人群食用，且生产工艺简单、卫生、安全、生产成本低，适合大范围推广普及。
中国专利202010293977.2中提供了具有改善骨胳状态、补充骨胳营养、缓解骨胳疼痛的一种改善骨胳的牛骨肽饮品及其制备方法，以牛骨胶原蛋白肽、大豆肽、鲨鱼软骨胶原蛋白肽、燕麦粉、奶粉、山药粉、葛根粉、当归粉、平卧菊三七、酵母葡聚糖、魔芋精粉、针叶樱桃、维生素D和维生素E加工制备成一种改善骨胳健康的牛骨肽饮品。这种牛骨肽饮品可明显改善骨质疏松，增强骨密度，补充骨胳钙，增强钙吸收活性，补充骨胳营养，易吸收，效果显著，起效周期短，制备工艺成熟，可大规模生产以用于人们的日常保健。
但现有技术中的牛骨肽复合产品在吸收速率，人体利用率和施用量上都有很大的优化空间。
发明内容
为了解决上述问题，本发明提供了一种新型复方骨肽，可应用于促进骨骼生长、促进钙质吸收、增强骨密度、改善骨质疏松。该复方骨肽吸收速率和吸收率均属于高水平，且临床施用量少，有广泛的应用前景。
一方面，本发明提供了一种新型复方骨肽。
所述的新型复方骨肽配方如下：
| 原料 | 配比％ |
| 牛骨多肽 | 12-16％ |
| Ⅱ型胶原蛋白肽 | 0.5-1.2％ |
| 酪蛋白磷酸肽 | 0.1-0.2％ |
| 乳清蛋白 | 35-45％ |
| 大豆分离蛋白 | 4-8％ |
| 酶解骨粉 | 3-3.5％ |
| 麦芽糊精 | 20-24％ |
| 维生素A、D、C | 0.1-0.4％ |
| 低聚果糖 | 8-12％ |
| 接骨木莓果汁粉 | 0.75-1.2％ |
| 姜黄 | 0.05-1％ |
| 黑胡椒提取物 | 0.005-0.2％ |
| 香精 | 0.05-1％ |
| 黄原胶 | 0.5-0.8％ |
| 三氯蔗糖 | 0.005-0.01％ |
。
优选地，所述的新型复方骨肽配方如下：
| 原料 | 配比％ |
| 牛骨多肽 | 15.000 |
| Ⅱ型胶原蛋白肽 | 0.850 |
| 酪蛋白磷酸肽 | 0.150 |
| 乳清蛋白 | 40.000 |
| 大豆分离蛋白 | 5.000 |
| 酶解骨粉 | 3.500 |
| 麦芽糊精 | 22.560 |
| 维生素A、D、C | 0.375 |
| 低聚果糖 | 10.000 |
| 接骨木莓果汁粉 | 0.750 |
| 姜黄 | 0.050 |
| 黑胡椒提取物 | 0.005 |
| 香精 | 1.000 |
| 黄原胶 | 0.750 |
| 三氯蔗糖 | 0.01 |
。
另一方面，本发明提供了前述的新型复方骨肽在制备药物或保健品中的应用。
所述的药物或保健品用于促进骨骼生长、促进钙质吸收、增强骨密度、改善骨质疏松。
再一方面，本发明提供了一种用于促进骨骼生长的药物或保健品。
所述的药物或保健品中包括前述的新型复方骨肽。
所述的药物或保健品中新型复方骨肽的含量为50-100％，优选为100％。
又一方面，本发明提供了一种新型复方骨肽的制备方法。
所述的制备方法用于制备前述的新型复方骨肽。
所述的制备方法中包括牛骨肽的制备。
所述的制备方法中包括以下步骤：
(1)牛骨脱脂；
(2)酶解底物制备；
(3)酶解；
(4)浓缩干燥。
具体地，所述的步骤(1)中采用高温蒸煮的方法进行脱脂；高温蒸煮采用脱脂罐为容器。
进一步地，所述的步骤(1)中脱脂罐中原料比例为牛骨：纯化水＝1：1；分离油脂的条件为温度70℃，真空度为-0.05MPa至-0.1MPa。
具体地，所述的步骤(2)中包括盐酸浸泡、维生素C水溶液浸泡。
具体地，所述的步骤(3)中包括酸性蛋白酶酶解、中性蛋白酶酶解。
在一些实施例中，所述的制备方法包括以下步骤：
(1)牛骨脱脂：
牛骨破碎至大小1-3cm加入脱脂罐；以1∶1比例向脱脂罐加入纯化水，沸煮3h；脱脂罐温度降至70℃左右，真空度为-0.05MPa至-0.1MPa，分离上层油脂；常压蒸煮：再以1∶1比例继续向脱脂罐内加纯化水，升温至100℃后，蒸煮3h；静置后，分离上层油脂；
(2)脱脂后牛骨置于质量分数为1％的盐酸溶液中浸泡4h；牛骨与盐酸溶液的用量比例为1kg：3L；
(3)牛骨粉碎并磨成骨泥，加入质量分数2％的维生素C水溶液中，浸泡6-8h得到酶解底物；牛骨与维生素C水溶液的用量比例为1kg：3L；
(4)按质量比1％加入酸性蛋白酶酶解2-3h；调整pH至7，按质量比1％加入中性蛋白酶酶解处理1-2h；酶解结束后，升温；
(5)过滤得到水解液；
(6)浓缩：将水解液采用刮板浓缩器浓缩得到质量分数30％的浓缩提取液；
(7)包埋干燥后制成颗粒；
(8)称重复配。
又一方面，本发明提供了前述的制备方法在制备用于促进骨骼生长的药物或保健品中的应用。
所述的药物或保健品用于促进骨骼生长、促进钙质吸收、增强骨密度、改善骨质疏松。
本发明提供的新型复方骨肽具有以下优点：
1、吸收速率快；
2、临床用量少；
3、吸收效率高。
附图说明
图1为血清中羟脯氨酸随时间含量变化图；其中，A：空白组；B：低剂量组(1.6g/kg)；C：中剂量组(3.2g/kg)；D：高剂量组(4.8g/kg)；E：骨肽片组(576mg/kg)；F：注射液组(90mg/kg)。
图2为小鼠血清中羟脯氨酸药时曲线面积计算结果。
图3为血清中三肽Gly-Pro-Hyp随时间含量变化图；其中，A：空白组；B：低剂量组(1.6g/kg)；C：中剂量组(3.2g/kg)；D：高剂量组(4.8g/kg)；E：骨肽片组(576mg/kg)；F：注射液组(90mg/kg)。
图4为三肽Gly-Pro-Hyp药时曲线面积计算结果。
具体实施方式
下面结合具体实施例，对本发明作进一步详细的阐述，下述实施例不用于限制本发明，仅用于说明本发明。以下实施例中所使用的实验方法如无特殊说明，实施例中未注明具体条件的实验方法，通常按照常规条件，下述实施例中所使用的材料、试剂等，如无特殊说明，均可从商业途径得到。
实施例1一种新型复方骨肽粉
配方如下：
实施例2一种新型复方骨肽的制备方法
本实施例制备的为实施例1提供的新型复方骨肽。包括以下步骤：
(1)牛骨脱脂：
牛骨破碎至大小1-3cm加入脱脂罐；以1∶1比例向脱脂罐加入纯化水，沸煮3h；脱脂罐温度降至70℃左右，真空度为-0.05MPa至-0.1MPa，分离上层油脂；常压蒸煮：再以1∶1比例继续向脱脂罐内加纯化水，升温至100℃后，蒸煮3h；静置后，分离上层油脂；
(2)脱脂后牛骨置于质量分数为1％的盐酸溶液中浸泡4h；牛骨与盐酸溶液的用量比例为1kg：3L；
(3)牛骨粉碎并磨成骨泥，加入质量分数2％的维生素C水溶液中，浸泡6-8h得到酶解底物；牛骨与维生素C水溶液的用量比例为1kg：3L；
(4)按质量比1％加入酸性蛋白酶酶解2-3h；调整pH至7，按质量比1％加入中性蛋白酶酶解处理1-2h；酶解结束后，升温；
(5)过滤得到水解液；
(6)浓缩：将水解液采用刮板浓缩器浓缩得到质量分数30％的浓缩提取液；
(7)包埋干燥后制成颗粒即为牛骨多肽。
按照实施例1中的成分进行称重复配。
以下实验例中选用的复方骨肽均为实施例1提供的复方骨肽。
以下实验例中，骨肽片购自吉林华康药业股份有限公司，国药准字H20058927；注射复方骨肽购自南京新百药业有限公司，国药准字H20003533。均于4℃干燥保存。
以下实验例中，血清的制备方法如下：小鼠眼球主动脉取出血液，置于具塞离心管中，常温静置30min后，4000rpm离心10min。用移液器缓慢取出上部血清置于另一具塞离心管中，用于血清指标的测定。
以下实验例中，新型复方骨肽用药量低剂量组为1.6g/kg；中剂量组为3.2g/kg；高剂量组为4.8g/kg。骨肽片组用药量为576mg/kg；注射液组用药量为90mg/kg。
实验例1检测血清中羟脯氨酸
选用健康的C57/BL小鼠，设置空白对照组，阳性药物对照组1(骨肽注射液组)、阳性药物对照组2(骨肽片组)、复方骨肽低、中、高剂量共6组，每组20只，均经适应性饲养一周后，于清晨分别给药一次。给药后，分别于1、3、6、12、24h后每组处死4只小鼠，取得每只小鼠的血浆，测定血清内羟脯氨酸含量(ELISA试剂盒)，比较样品的生物利用度情况。计算血清内羟脯氨酸药时曲线下面积AUC，比较样品药物吸收的有效暴露量。
结果如图1所示。
由图1可以得出实验组小鼠血清中羟脯氨酸的含量均有明显的增加。随着骨肽样品剂量的提高，血清中羟脯氨酸的含量水平也随之提高；且骨肽样品灌胃小鼠血清中羟脯氨酸含量在灌胃3h后，就基本达到了最高水平，而且随着时间的延长羟脯氨酸含量一直保持较高水平，在24h后都未发生明显下降。说明骨肽样品吸收速率明显高于骨肽片和骨肽注射液。
实验例2三肽Gly-Pro-Hyp检测
阳性药物对照组和实验组饲养给药同实验例1。给药(注射或灌胃)后，分别于1、3、6、12、24h后每组处死4只小鼠，取得每只小鼠的血清，测定血清中三肽Gly-Pro-Hyp(甘氨酸-脯氨酸-羟脯氨酸)的含量(采用标品Pro-Hyp-Gly高效液相色谱法测定含量)，比较样品的生物利用度情况。计算血清内三肽Gly-Pro-Hyp药时曲线下面积AUC，比较样品药物吸收的有效暴露量。
小鼠血清中羟脯氨酸药时曲线面积如图2所示。药时曲线下面积AUC是以给药后血药浓度为纵坐标，以时间为横坐标所得曲线下的面积。本实验中使用积分法求得，其可以表示服用某一剂量药物后一定时间内药物吸收入血的相对分量，与生物体吸收循环的药量成正比。通过图2可以看出，随骨肽样品剂量的提高，其羟脯氨酸AUC值随之提高。且低剂量、中剂量、高剂量骨肽样品的羟脯氨酸AUC远高于临床剂量骨肽注射液组与骨肽片组，证明了骨肽样品有效吸收的优势。说明，临床使用剂量——低剂量组的有效暴露明显高于骨肽注射液和骨肽片。
血清中三肽Gly-Pro-Hyp随时间含量变化图如图3所示。由图3可以得出各实验组小鼠血清中三肽Gly-Pro-Hyp的含量均有明显的增加。随着骨肽样品剂量的提高，血清中Gly-Pro-Hyp的含量水平也随之提高；且骨肽样品灌胃小鼠血清中三肽Gly-Pro-Hyp在灌胃3h后，就达到了最高水平；而且随着时间的延长，Gly-Pro-Hyp含量一直保持较高水平，在24h都未发生明显下降。说明骨肽样品吸收率明显高于骨肽片和骨肽注射液。
三肽Gly-Pro-Hyp药时曲线面积如图4所示。本实验中使用积分法求得Gly-Pro-Hyp含量的药时曲线下面积，从图4中可以看出，随骨肽样品剂量的提高，其Gly-Pro-Hyp的AUC值随之提高。且低剂量、中剂量、高剂量骨肽样品远高于临床剂量骨肽注射液组与骨肽片组，证明了骨肽样品有效吸收的优势。说明，临床使用剂量——低剂量骨肽样品的药物暴露明显高于骨肽注射液和骨肽片。
由实验例1-2结果可知，小鼠骨肽样品吸收速率明显高于骨肽片和骨肽注射液，且骨肽样品发挥作用的时间明显长于骨肽片和骨肽注射液。
通过对羟脯氨酸及三肽Gly-Pro-Hyp进行药代数学模型的模拟，利用积分法求得药时曲线下面积(AUC)。对比结果发现，随着新型骨肽配方样品剂量的提高，其AUC值也随之提高，证明小鼠吸收骨肽样品的有效暴露量增加。且低剂量骨肽样品组羟脯氨酸的AUC和三肽Gly-Pro-Hyp的AUC明显高于临床剂量骨肽注射液与骨肽片组。说明，临床使用剂量——低剂量骨肽样品的药物暴露明显高于骨肽注射液和骨肽片。
结果表明：
1、采用复配的骨肽可以使标志性营养活性成分羟脯氨酸和三肽达到高浓度，效果等同或优于同类药品效果。
2、合适的复方成分比例高效率综合解决骨骼等多种综合性问题。
3、配方口感顺滑，依从性好，适合持续使用。
对比例
设置对比例并参考实验例1-2的方法对对比例和实施例1进行检测，检测时均参考高剂量组进行操作。
对比例设置如下：
实验结果如下：
Claims (6)
1.一种新型复方骨肽，其特征在于，配方如下：
；
所述的新型复方骨肽制备方法包括以下步骤：
S1、牛骨脱脂：牛骨破碎至大小1-3cm加入脱脂罐；以1∶1比例向脱脂罐加入纯化水，沸煮3h；脱脂罐温度降至70℃，真空度为-0.05MPa至-0.1MPa，分离上层油脂；常压蒸煮：再以1∶1比例继续向脱脂罐内加纯化水，升温至100℃后，蒸煮3h；静置后，分离上层油脂；
S2、脱脂后牛骨置于质量分数为1％的盐酸溶液中浸泡4h；牛骨与盐酸溶液的用量比例为1kg：3L；
S3、牛骨粉碎并磨成骨泥，加入质量分数2％的维生素C水溶液中，浸泡6-8h得到酶解底物；牛骨与维生素C水溶液的用量比例为1kg：3L；
S4、按质量比1％加入酸性蛋白酶酶解2-3h；调整pH至7，按质量比1％加入中性蛋白酶酶解处理1-2h；酶解结束后，升温；
S5、过滤得到水解液；
S6、浓缩：将水解液采用刮板浓缩器浓缩得到质量分数30％的浓缩提取液；
S7、包埋干燥后制成颗粒即为牛骨多肽。
2.根据权利要求1所述的新型复方骨肽，其特征在于，配方如下：
。
3.权利要求1-2任一项所述的新型复方骨肽在制备药物或保健品中的应用，其特征在于，所述的药物或保健品用于促进骨骼生长、促进钙质吸收、增强骨密度、改善骨质疏松。
4.一种用于促进骨骼生长的药物或保健品，其特征在于，所述的药物或保健品中包括权利要求1-2任一项所述的新型复方骨肽。
5.根据权利要求4所述的药物或保健品，其特征在于，所述的药物中新型复方骨肽的含量为50％-100％。
6.根据权利要求5所述的药物或保健品，其特征在于，所述的药物中新型复方骨肽的含量为100％。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111182578.XA CN113854574B (zh) | 2021-10-11 | 2021-10-11 | 一种新型复方骨肽及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111182578.XA CN113854574B (zh) | 2021-10-11 | 2021-10-11 | 一种新型复方骨肽及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113854574A CN113854574A (zh) | 2021-12-31 |
| CN113854574B true CN113854574B (zh) | 2023-11-10 |
Family
ID=78999003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111182578.XA Active CN113854574B (zh) | 2021-10-11 | 2021-10-11 | 一种新型复方骨肽及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113854574B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114617267A (zh) * | 2022-03-22 | 2022-06-14 | 意润健康产业（广州）有限公司 | 一种强化型复合骨肽及其制备方法与应用 |
| CN119074902A (zh) * | 2024-08-28 | 2024-12-06 | 天津橙悦生物科技有限公司 | 一种可以改善骨质疏松缓解关节炎的牛骨蛋白肽组合物的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106222225A (zh) * | 2016-08-31 | 2016-12-14 | 湖北瑞邦生物科技有限公司 | 一种牛骨活性肽的制备方法 |
| CN113261671A (zh) * | 2021-05-27 | 2021-08-17 | 杭州佰倍优生物科技有限公司 | 一种用于预防和改善骨质疏松的牛骨肽组合物及其应用 |
-
2021
- 2021-10-11 CN CN202111182578.XA patent/CN113854574B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106222225A (zh) * | 2016-08-31 | 2016-12-14 | 湖北瑞邦生物科技有限公司 | 一种牛骨活性肽的制备方法 |
| CN113261671A (zh) * | 2021-05-27 | 2021-08-17 | 杭州佰倍优生物科技有限公司 | 一种用于预防和改善骨质疏松的牛骨肽组合物及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| 施杞等.常见骨伤疾病的中医预防和护养.复旦大学出版社,2013,(第1版),176. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113854574A (zh) | 2021-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113854574B (zh) | 一种新型复方骨肽及其应用 | |
| CN107950851A (zh) | 一种无苦味复合多肽粉 | |
| CN104257583B (zh) | 一种珍珠酶解液及其制备方法 | |
| CN109757733A (zh) | 一种口服多肽粉及其制备方法和应用 | |
| CN109757732A (zh) | 一种口服流质多肽粉及其制备方法 | |
| CN111658681A (zh) | 一种复合食用菌蛋白粉的制备方法及其应用 | |
| CN112569305A (zh) | 一种提高免疫力的香菇复合多糖组合物及其制备方法 | |
| CN101664180B (zh) | 一种具有保健功效的营养复合剂及其制备方法 | |
| CN109180788B (zh) | 一种骆驼奶抗氧化多肽的制备方法及其应用 | |
| CN103564495B (zh) | 一种蜂胶和虫草菌丝粉组合物及制备和应用 | |
| CN101156681B (zh) | 一种复合多肽营养健康食品 | |
| CN1430975A (zh) | 一种海洋星虫提取物及制备方法和应用 | |
| CN107348365A (zh) | 一种新型纳豆多肽保健食品 | |
| CN101612306B (zh) | 一种提高免疫力缓解疲劳的中药组合物及其制备方法 | |
| CN105535425B (zh) | 一种具有增强免疫力作用的中药组合物及其制备方法与用途 | |
| CN107279458A (zh) | 一种具有增强机体免疫力的富锌豌豆小肽及其制备方法 | |
| CN114848727B (zh) | 一种西洋参膏的制备方法和应用 | |
| WO2016141774A1 (zh) | 吉林人参低聚肽在制备改善和增强性功能的食品或保健食品中的用途 | |
| CN108402459A (zh) | 乌鳢乌鸡本草组合物及其制备方法和应用 | |
| CN109497470A (zh) | 一种蛋白核小球藻多肽缓解增肥组合物及其制备方法 | |
| CN107266599A (zh) | 金针菇多糖、提取方法及其在制备治疗功能性便秘药物方面的应用 | |
| CN114009793A (zh) | 一种人参海参鳄鱼肽组合物及其制备方法 | |
| CN115702654A (zh) | 辅助降血糖的中老年调制羊奶粉及制备方法 | |
| CN113100442A (zh) | 一种蜂王浆龟鳖肽嚼含片及其制备工艺 | |
| CN111227229A (zh) | 一种植物源营养粉及其制备方法和食用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20211231 Assignee: Hangzhou Haihuan Nutritional Food Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000936 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Hangzhou Chendaokou E-commerce Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000935 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Hangzhou Baibeiyou Nutritional Food Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000934 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Guangzhou Hangyi Trading Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000933 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Hangzhou Baibeiyou E-commerce Technology Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000932 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Hangzhou Ailiwei Trading Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000931 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Hangzhou Shutikang Biotechnology Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000943 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Hangzhou Guangyoujiu Enterprise Management Partnership (L.P.) Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000942 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Guangzhou Xuyang Trading Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000941 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Hangzhou Ximazhai Nutritional Food Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000940 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Hangzhou Shimengze Biotechnology Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000939 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Hangzhou Shanlibai Trading Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000938 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 Application publication date: 20211231 Assignee: Hangzhou Liangmeiyan Trading Co.,Ltd. Assignor: Hangzhou baibeiyou Biotechnology Co.,Ltd. Contract record no.: X2023330000937 Denomination of invention: A novel compound bone peptide and its application Granted publication date: 20231110 License type: Common License Record date: 20231221 |
|
| EE01 | Entry into force of recordation of patent licensing contract |